Research Analysts Issue Forecasts for CRBP Q2 Earnings

Key Points

• B. Riley estimates that Corbus Pharmaceuticals (NASDAQ:CRBP) will report a Q2 2025 earnings loss of ($1.63) per share, maintaining a "Strong-Buy" rating with a target price of $28.00.
• The consensus estimate for Corbus Pharmaceuticals' full-year earnings is anticipated to be ($4.23) per share, with projected losses continuing over the next few fiscal years.
• Corbus Pharmaceuticals' stock has experienced a strong 342% year-to-date surge, but has seen target price reductions from various financial institutions in the past months.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - B. Riley issued their Q2 2025 EPS estimates for shares of Corbus Pharmaceuticals in a research note issued on Wednesday, July 30th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will post earnings of ($1.63) per share for the quarter. B. Riley has a "Buy" rating and a $28.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals' Q3 2025 earnings at ($1.63) EPS, Q4 2025 earnings at ($1.63) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($5.49) EPS and FY2027 earnings at ($5.50) EPS.

A number of other equities research analysts also recently issued reports on the stock. Oppenheimer cut their price objective on shares of Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Royal Bank Of Canada dropped their target price on shares of Corbus Pharmaceuticals from $65.00 to $58.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. HC Wainwright dropped their target price on shares of Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Lifesci Capital raised shares of Corbus Pharmaceuticals to a "strong-buy" rating in a report on Saturday, July 12th. One analyst has rated the stock with a sell rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $49.38.

Corbus Pharmaceuticals Stock Performance

Shares of CRBP stock traded up $0.04 during mid-day trading on Friday, reaching $9.31. 122,153 shares of the company's stock traded hands, compared to its average volume of 122,735. Corbus Pharmaceuticals has a 12 month low of $4.64 and a 12 month high of $61.89. The firm has a 50 day moving average price of $8.32 and a two-hundred day moving average price of $7.82. The firm has a market capitalization of $113.95 million, a PE ratio of -2.21 and a beta of 3.20.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.13).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CRBP. Exome Asset Management LLC bought a new position in shares of Corbus Pharmaceuticals in the 1st quarter valued at about $1,538,000. Millennium Management LLC lifted its holdings in shares of Corbus Pharmaceuticals by 215.0% in the 4th quarter. Millennium Management LLC now owns 386,653 shares of the biopharmaceutical company's stock valued at $4,563,000 after acquiring an additional 263,902 shares during the last quarter. Orbimed Advisors LLC lifted its holdings in shares of Corbus Pharmaceuticals by 28.5% in the 4th quarter. Orbimed Advisors LLC now owns 1,172,287 shares of the biopharmaceutical company's stock valued at $13,833,000 after acquiring an additional 259,735 shares during the last quarter. Comerica Bank lifted its holdings in shares of Corbus Pharmaceuticals by 20,000,000.0% in the 1st quarter. Comerica Bank now owns 200,001 shares of the biopharmaceutical company's stock valued at $1,062,000 after acquiring an additional 200,000 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Corbus Pharmaceuticals in the 1st quarter valued at about $1,007,000. Institutional investors own 64.64% of the company's stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.